Estimating protein binding upon treatment with radionuclide ions.

Area of Science:

• Biochemistry
• Radiochemistry
• Computational Chemistry

Background:

• Radioactive isotopes are crucial in cancer therapy, but their administration methods vary.
• Free ionic radionuclides can interfere with protein function by binding to sites meant for endogenous ions.
• Understanding these interactions is vital for optimizing radionuclide therapy safety and efficacy.

Purpose of the Study:

• To computationally assess the binding affinities of Y3+, Ra2+, and Pb2+ to proteins.
• To evaluate the potential of these ions to displace native cofactors like Ca2+ and Mn2+.
• To inform the development of safer and more effective radionuclide-based cancer treatments.

Main Methods:

• Utilized computational methods to model and predict ion-protein interactions.
• Focused on the binding sites of calcium (Ca2+) and manganese (Mn2+) cofactors.
• Assessed the binding affinity of Y3+, Ra2+, and Pb2+ in place of these native ions.

Main Results:

• Yttrium (Y3+) demonstrated strong binding to proteins, capable of replacing Ca2+ and, to a lesser extent, Mn2+.
• Radium (Ra2+) showed no significant binding to the studied proteins.
• Lead (Pb2+), a decay product of 223Ra, was found to bind to Ca2+-binding proteins, potentially displacing Ca2+.

Conclusions:

• Y3+ and Pb2+ exhibit potential for unintended protein interactions, impacting cancer therapy strategies.
• Ra2+ appears to have a lower risk of direct protein binding compared to Y3+ and Pb2+.
• The findings support the need for careful consideration of radionuclide ion behavior in therapeutic applications and highlight the selectivity of a new coordination compound for 223Ra.